Compass Therapeutics Inc.
NASDAQ:CMPX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Road Environment Technology Co Ltd
SSE:688156
|
CN |
|
B
|
Beijing Zuojiang Technology Co Ltd
SZSE:300799
|
CN |
|
Matsuya Foods Holdings Co Ltd
TSE:9887
|
JP |
|
C
|
China Chippacking Technology Co Ltd
SSE:688216
|
CN |
|
E
|
Envela Corp
AMEX:ELA
|
US |
|
Lvji Technology Holdings Inc
HKEX:1745
|
CN |
|
Bellway PLC
LSE:BWY
|
UK |
|
Eastman Kodak Co
NYSE:KODK
|
US |
|
Y
|
Yinfu Gold Corp
OTC:ELRE
|
CN |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (14.3), the stock would be worth $-7.25 (221% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -11.8 | $6 |
0%
|
| Industry Average | 14.3 | $-7.25 |
-221%
|
| Country Average | 19.6 | $-9.96 |
-266%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
C
|
Compass Therapeutics Inc.
NASDAQ:CMPX
|
1.1B USD | -11.8 | -16.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
368.4B USD | 20.3 | 88 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
191.5B USD | 14.4 | 24.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.9B USD | 15.5 | 20.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.7B USD | 22.2 | 28.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 14.9 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
44.4B EUR | 44.6 | 40.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.3B AUD | 13.7 | 32.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Compass Therapeutics Inc.
Glance View
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-11-13. Its pipeline of product candidates includes both angiogenesis-targeted agents and immune-oncology focused agents. These product candidates are designed for anti-tumor response to cancer. Its lead product candidate, CTX-471, is a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells. Its second product candidate, CTX-8371, is a bispecific antibody that simultaneously targets both PD-1 and PD-L1, the targets of checkpoint inhibitor antibodies. In addition to CTX-471 and CTX-8371, It is also developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. Its product candidate, CTX-009, is an anti-DLL4 x VEGF-A bispecific antibody, which has added to its pipeline through Trigr Therapeutics, Inc. (TRIGR).
